ACD/Labs

Based in Canada, Advanced Chemistry Development, Inc. , dba ACD/Labs offers specialized software solutions for research and development in chemistry and related fields, enabling effective data management and decision-making for scientific research. Founded in 1994 in Toronto, Canada, ACD/Labs provides software solutions that cater to the needs of the chemistry and scientific research community. In November 2025, Revvity, Inc.

, a portfolio company of New Mountain Capital, agreed to acquire ACD/Labs. The transaction is expected to close in Q4 2025. ACD/Labs specializes in providing advanced software solutions tailored for research and development in the fields of chemistry and related sciences. Their core offerings include the Spectrus and Percepta platforms, which focus on analytical data management, molecular property prediction, and decision support.

These software solutions are designed to streamline complex workflows, enhance collaboration among research teams, and facilitate data-driven decision-making. ACD/Labs products cater to a diverse clientele, including top pharmaceutical and biopharmaceutical companies, academic institutions, and research organizations globally. The software is utilized in various geographical markets, with significant presence in North America, Europe, and Asia, addressing the unique needs of scientific research in these regions. ACD/Labs operates under a subscription-based revenue model, providing access to its software products through annual contracts.

Clients typically engage in B2B transactions, purchasing licenses for the flagship products such as Spectrus and ChemSketch, which are aimed at enhancing laboratory efficiency and data analysis. The pricing structure is tiered based on the specific solutions and features selected by the client, allowing for scalable integration into existing workflows. The company’s customer base includes leading pharmaceutical companies and prominent universities, which rely on ACD/Labs software for its robust capabilities in analytical prediction and simulation. This transaction model fosters long-term partnerships, ensuring that clients receive continuous updates and support, thus reinforcing their commitment to cutting-edge scientific research.

In November 2025, Revvity, Inc. , a portfolio company of New Mountain Capital, agreed to acquire ACD/Labs, although financial terms were not disclosed. This acquisition aims to strengthen Revvity's Signals software capabilities and expand its informatics offerings for scientific research. Future strategies include the development of new products to enhance their existing software suite, focusing on specific needs in scientific research.

The company is also likely to explore expansions into new geographical markets, although specific regions have not been disclosed. Recent funding will support these initiatives by enabling the development of advanced software solutions and enhancing operational capabilities.